Bone morphogenetic proteins (BMPs), at first recognized as osteoinductive additives in extracts derived from bone, are now known to play vital roles in a big selection of processes throughout formation and renovation of diverse organs such as bone, cartilage, muscle, kidney, and blood vessels. BMPs and the related “growth and differentiation factors” (GDFs) are individuals of the transforming boom component β (TGF-β) family, and transduce their indicators through type I and type II serine-threonine kinase receptors and their intracellular downstream effectors, such as Smad proteins. Furthermore, BMP indicators are finely tuned by various agonists and antagonists. Because deregulation of the BMP interest at more than one steps in sign transduction is linked to a wide style of human diseases, healing use of activators and inhibitors of BMP signaling will provide capacity avenues for the treatment of the human disorders that are caused by hypo- and hyperactivation of BMP indicators, respectively. Bone morphogenetic proteins (BMPs) are a collection of multi-functional increase factors in the transforming growth component β (TGF-β) superfamily, firstly discovered due to their robust bone-inducing hobby. BMPs have also been proven to play important roles in embryogenesis and development in addition to the renovation of adult tissue homeostasis, which include bone, cartilage, muscle, kidney and blood vessels. Such biological activities have led to great interest inside the development of clinical remedies concentrated on BMP signalling complexes. Recombinant human BMP2 and BMP7 have acquired approval from the United States Food and Drug Administration (FDA) for treating open tibial shaft fractures and long bone non-unions respectively. Since then, many scientific reports were published demonstrating the efficacy of BMPs in restoring many varieties of bone defects in man. However, in an effort to attain the powerful osteoinductive pastime, a excessive dosage of BMPs should be administrated to patients, resulting in excessive costs. In addition, it has been reported that the manufacturing of autoantibodies due to the administration of allogenic or xenogenic BMPs may additionally hinder the usage of BMPs in clinical applications. Furthermore, big organic molecules like recombinant BMPs showcase early burst release and degradation issues when integrated with vendors in a biological environment. These drawbacks have inspired interest within the development of greater cost-effective BMP-primarily based healing procedures.